FDA Inspection 1007184 — GlaxoSmithKline Biologicals SA
The FDA completed an inspection of GlaxoSmithKline Biologicals SA on January 27, 2017 in Rixensart. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Biologics.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- January 27, 2017
- Fiscal Year
- 2017
- Product Type
- Biologics
- Project Area
- Vaccines and Allergenic Products
- Location
- Rixensart (Belgium)